Rapamycin golden jubilee and still the miraculous drug: a potent immunosuppressant, antitumor, rejuvenative agent, and potential contributor in COVID-19 treatment

Abstract

Although celebrating its golden jubilee, rapamycin’s importance keeps increasing by the day. Starting as a promising antifungal agent, then as a potent immunosuppressant, strong anticancer drug, and now rapamycin is attracting serious attention as a rejuvenative agent and a possible contributor in treating this era pandemic, COVID-19. Due to its diverse biological activities and promising medical applications, we aimed in this review to put rapamycin under the spot and highlight its discovery, famous microbial producers, reported biological activities, chemical structure, famous analogues, and biosynthesis. Moreover, discuss some rapamycin production approaches including solid-state fermentation, and stressing out producing strain. On the other hand, describe its action mechanism and trials to use it in treatment of COVID-19. Additionally, we highlighted some of the side effects accompanying its use, and describe some approaches reported to minimize these undesired effects. Finally, we report the current status of rapamycin and its analogues in global market, and discuss future prospects of this potent drug.

Keywords

Rapamycin / Biosynthesis / Gene cluster

References

[1] Arena C, Bizzoca ME, Caponio VCA, Troiano G, Zhurakivska K, Leuci S, Lo Muzio L. Everolimus therapy and side-effects: a systematic review and meta-analysis. Int J Oncol, 2021, 59: 1-9.

[2] Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, Pumper CP, Kimple ME, Lamming DW. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell, 2016, 15(1): 28-38.

[3] Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE, Lamming DW. Intermittent administration of rapamycin extends the life span of female C57BL/6J mice. J Gerontol Ser a: Biomed Sci Med Sci, 2016, 71(7): 876-881.

[4] Atkins MB, Yasothan U, Kirkpatrick P. Everolimus. Na Rev Drug Discov, 2009

[5] Baker H, Sidorowicz A, Sehgal SN, VÉZINA C. RapamyciN (AY-22, 989), a new antifungal antibiotic in vitro and in vivo evaluation. J Antibio, 1978, 31(6): 539-545.

[6] Bischof E, Siow R, Zhavoronkov A, Kaeberlein M. The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. Lancet Healthy Longev, 2021, 2(2): e105-e111.

[7] Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today, 2007, 12(5–6): 218-224.

[8] Blagosklonny MV. From causes of aging to death from COVID-19. Aging, 2020, 12(11): 10004. albany NY

[9] Boni JP, Hug B, Leister C, Sonnichsen D. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Sem Oncol, 2009, 36(1): S18-S25.

[10] Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev, 2006, 58(3): 437-446.

[11] Cantaluppi V, Biancone L, Romanazzi GM, Figliolini F, Beltramo S, Ninniri MS, Galimi F, Romagnoli R, Franchello A, Salizzoni M, Perin PC. Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transpl, 2006, 6(11): 2601-2611.

[12] Chapman TM, Perry CM. Everolimus. Drugs, 2004, 64(8): 861-872.

[13] Cheaib B, Auguste A, Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer, 2015, 34(1): 4-16.

[14] Chen YW, Smith ML, Sheets M, Ballaron S, Trevillyan JM, Burke SE, Rosenberg T, Henry C, Wagner R, Bauch J, Marsh K. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J Cardiovasc Pharmacol, 2007, 49(4): 228-235.

[15] Cheng YR, Fang A, Demain AL. Effect of amino acids on rapamycin biosynthesis by Streptomyces hygroscopicus. Appl Microbiol Biotechnol, 1995, 43(6): 1096-1098.

[16] Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med, 2008, 5(1

[17] Dai DF, Karunadharma PP, Chiao YA, Basisty N, Crispin D, Hsieh EJ, Chen T, Gu H, Djukovic D, Raftery D, Beyer RP. Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell, 2014, 13(3): 529-539.

[18] Dancey JE, Monzon J. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. Future Oncol, 2011, 7(7): 827-839.

[19] Dang T, Thompson H, Liu V, Kwong B. Liu V. Dermatologic adverse effects of anticancer therapy III: targeted and immunotherapies. Dermato-oncology study guide, 2021, Cham: Springer, 273-316.

[20] De Masson A, Fouchard N, Mery-Bossard L, Dauendorffer JN. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors. Dermatology, 2011, 223(1): 4-8.

[21] Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev, 1981, 8(1): 63-87.

[22] Dumas SN, Lamming DW. Next generation strategies for geroprotection via mTORC1 inhibition. J Gerontol: Ser A, 2020, 75(1): 14-23.

[23] Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci, 1995, 58(5): 373-395.

[24] Ekici Y, Emiroglu R, Ozdemir H, Aldemir D, Karakayali H, Haberal M. Effect of rapamycin on wound healing: an experimental study. Transpl Proc, 2007, 39: 1201-1203.

[25] Falke LL, van Vuuren SH, Kazazi-Hyseni F, Ramazani F, Nguyen TQ, Veldhuis GJ, Maarseveen EM, Zandstra J, Zuidema J, Duque LF, Steendam R. Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres. Biomaterials, 2015, 42: 151-160.

[26] Fang A, Demain AL. Exogenous shikimic acid stimulates rapamycin biosynthesis in Streptomyces hygroscopicus. Folia Microbiol, 1995, 40(6): 607-610.

[27] Fireman M, DiMartini AF, Armstrong SC, Cozza KL. Immunosuppressants. Psychosomatics, 2004, 45(4): 354-360.

[28] Garber K. Rapamycin’s resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst, 2001, 93(20): 1517-1519.

[29] Ghasemnejad-Berenji M. mTOR inhibition: a double-edged sword in patients with COVID-19?. Hum Cell, 2021, 34(2): 698-699.

[30] Graziani EI, Summers MY, Overk CR, Ritacco FV, Zabriskie T, Yu K, Bernan VS, Greenstein M, Carter GT. Understanding natural product biosynthesis: novel analogs of rapamycin and neutramycin, 2003, Washington DC: In abstracts of papers of the American Chemical Society 1155 16TH ST, NW DC 20036 USA: Amer chemical Soc. 226: U103-U103

[31] Gregory MA, Gaisser S, Lill RE, Hong H, Sheridan RM, Wilkinson B, Petkovic H, Weston AJ, Carletti I, Lee HL, Staunton J, Leadlay PF. Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus. Angew Chem Int Ed, 2004, 43: 2551-2553.

[32] Guarda E, Marchant E, Fajuri A, Martínez A, Morán S, Mendez M, Uriarte P, Valenzuela E, Lazen R. Oral rapamycin to prevent human coronary stent restenosis: a pilot study. Am Heart J, 2004, 148(2): 341-343.

[33] Guimarães I, Tessarollo NG, Lyra-Junior P, dos Santos DZ, Zampier RC, de Oliveira LF, Siqueira KV, Silva IV, Rangel LB. Rangel LBA IV, Silva. Targeting the PI3K/AKT/mTOR pathway in cancer cells. Updates on cancer treatment, 2015, InTech: Houston, 1-10.

[34] Hambright WS, Philippon MJ, Huard J. Rapamycin for aging stem cells. Aging, 2020, 12(15): 15184. albany NY

[35] Hasbal NB, Turgut D, Oguz EG, Ulu S, Gungor O. Effect of calcineurin inhibitors and mammalian target of rapamycin inhibitors on the course of covid-19 in kidney transplant recipients. Ann Transplant, 2021, 26: e929279-e929281.

[36] Huang H, Shuang-Xi R, Sheng YA, Hai-Feng HU. Comparative analysis of rapamycin biosynthesis clusters between actinoplanes sp N902–109 and Streptomyces hygroscopicus ATCC29253. Chinese J Nat Med, 2015, 13(2): 90-98.

[37] Husain A, Byrareddy SN. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19. Chem Biol Interact, 2020, 331.

[38] Johnson SC, Kaeberlein M. Rapamycin in aging and disease: maximizing efficacy while minimizing side effects. Oncotarget, 2016, 7(29): 44876.

[39] Kaeberlein M. mTOR inhibition: from aging to autism and beyond. Scientifica, 2013

[40] Karp A. Rapamycin and metformin in treating COVID-19. Sci J Lander Coll Arts Sci, 2021, 14(2): 43-51.

[41] Khalil RB. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia. Med Hypotheses, 2020, 142.

[42] Kojima I, Cheng Y, Mohan V, Demain AL. Carbon source nutrition of rapamycin biosynthesis in Streptomyces hygroscopicus. J Ind Microbiol, 1995, 14(6): 436-439.

[43] Krishna C. Solid-state fermentation systems—an overview. Crit Rev Biotechnol, 2005, 25(1–2): 1-30.

[44] Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Investig, 2013, 123(3): 980-989.

[45] Le Tourneau C, Faivre S, Serova M, Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?. Br J Cancer, 2008, 99(8): 1197-1203.

[46] Maiese K. The mechanistic target of rapamycin (mTOR): novel considerations as an antiviral treatment. Curr Neurovasc Res, 2020, 17(3): 332-337.

[47] Manan MA, Webb C. Estimation of growth in solid state fermentation: a review. Malays J Microbiol, 2018, 14(1): 61-69.

[48] Martel J, Chang SH, Wu CY, Peng HH, Hwang TL, Ko YF, Young JD, Ojcius DM. Recent advances in the field of caloric restriction mimetics and anti-aging molecules. Ageing Res Rev, 2021, 66.

[49] Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs, 2008, 17(12): 1947-1954.

[50] Mohamed MA, Elkhateeb WA, Daba GM. The continuous story of the miraculous drug, rapamycin. ARC. J Pharm Sci, 2019, 5: 1-7.

[51] Mohamed MA, Elkhateeb WA, Taha MA, Daba GM. New strategies in optimization of rapamycin production by Streptomyces hygroscopicus ATCC 29253. Res J Pharm Technol, 2019, 12(9): 4197-4204.

[52] Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit, 2002, 24(1): 53-58.

[53] Nlshida H, Sakakibara T, Aoki F, Saito T, Ichikawa K, Inagaki T, Kojima Y, Yamauchi Y, Huang LH, Guadliana MA, Kaneko T. Generation of novel rapamycin structures by microbial manipulations. J Antibiot, 1995, 48(7): 657-666.

[54] Nührenberg TG, Voisard R, Fahlisch F, Rudelius M, Braun J, Gschwend J, Kountides M, Herter T, Baur R, Hombach V, Baeuerle PA. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J, 2005, 19(2): 1-21.

[55] Omae K, Kondo T, Takagi T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K. Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience with four cases. Hemodial Int, 2016, 20(3): E1-E5.

[56] Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. Clin Immunol, 2020, 216.

[57] Paiva NL, Demain AL, Roberts MF. Incorporation of acetate, propionate, and methionine into rapamycin by Streptomyces hygroscopicus. J Nat Prod, 1991, 54(1): 167-177.

[58] Paiva NL, Demain AL, Roberts MF. The immediate precursor of the nitrogen-containing ring of rapamycin is free pipecolic acid. Enzyme Microb Technol, 1993, 15(7): 581-585.

[59] Paiva NL, Roberts MF, Demain AL. The cyclohexane moiety of rapamycin is derived from shikimic acid in Streptomyces hygroscopicus. J Ind Microbiol Biotechnol, 1993, 12(6): 423-428.

[60] Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf, 2013, 12(2): 177-186.

[61] Paplomata E, Zelnak A, O’Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat, 2013, 140(3): 453-462.

[62] Park SR, Yoo YJ, Ban YH, Yoon YJ. Biosynthesis of rapamycin and its regulation: past achievements and recent progress. J Antibiot, 2010, 63(8): 434-441.

[63] Patocka J, Kuca K, Oleksak P, Nepovimova E, Valis M, Novotny M, Klimova B. Rapamycin: drug repurposing in SARS-CoV-2 infection. Pharmaceuticals, 2021, 14(3): 217.

[64] Reynolds KA, Demain AL. Strohl WR. Rapamycin, FK506 and ascomycin-related compounds. Biotechnology of antibiotics, 1997, 2, NY, USA: Marcel Dekker, 497-520.

[65] Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther, 2011, 10(6): 1059-1071.

[66] Savvoulidis P, Perlman G, Bagur R. The EluNIRTM ridaforolimus eluting coronary stent system. Expert Rev Med Devices, 2019, 16(1): 71-76.

[67] Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation, 1997, 64(1): 36-42.

[68] Schwecke T, Aparicio JF, Molnar I, König A, Khaw LE, Haydock SF, Oliynyk M, Caffrey P, Cortes J, Lester JB. The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. Proc Natl Acad Sci, 1995, 92(17): 7839-7843.

[69] Seto B. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med, 2012, 1(1): 1-7.

[70] Singhania RR, Patel AK, Soccol CR, Pandey A. Recent advances in solid-state fermentation. Biochem Eng J, 2009, 44(1): 13-18.

[71] Song Y, Xue H, Liu TT, Liu JM, Chen D. Rapamycin plays a neuroprotective effect after spinal cord injury via anti-inflammatory effects. J Biochem Mol Toxicol, 2015, 29(1): 29-34.

[72] Su D, Mita M, Mita AC. Mita M, Mita A, Rowinsky EK. The clinical pharmacology and toxicity profile of rapalogs. mTOR inhibition for cancer therapy: past, present and future, 2016, Paris: Springer, 161-189.

[73] Świtaj T, Sobiborowicz A, Teterycz P, Klimczak A, Makuła D, Wągrodzki M, Szumera-Ciećkiewicz A, Rutkowski P, Czarnecka AM. Efficacy of sirolimus treatment in PEComa–10 years of practice perspective. J Clin Med, 2021, 10(16): 3705.

[74] Tsang CK, Qi H, Liu LF, Zheng XS. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today, 2007, 12(3 4): 112-124.

[75] Vedantham K, Chaterji S, Kitsongsermthon J, Park K, Garner J. Future outlook for drug eluting stents, 2010, In Drug-Device Combination Products: Woodhead Publishing

[76] Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY22, 989), a new antifungal antibiotic. I. taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot, 1975, 28: 721-726. tokyo

[77] Viana SD, Reis F, Alves R. Therapeutic use of mTOR inhibitors in renal diseases: advances, drawbacks, and challenges. Oxid Med Cell Longev, 2018

[78] Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol, 2007, 27: 495-502.

[79] Yoo YJ, Kim H, Park SR, Yoon YJ. An overview of rapamycin: from discovery to future perspectives. J Ind Microbiol Biotechnol, 2017, 44(4–5): 537-553.

[80] Chiang MH (2015) Fermentation of Streptomyces hygroscopicus for rapamycin production and the purification process development by using macroporous adsorption resins PhD dissertation Tunghai University Taiwan

[81] De Vera AA Reznik SE (2019) Combining PI3K/Akt/mTOR inhibition with chemotherapy In protein kinase inhibitors as sensitizing agents for chemotherapy Academic Press 229–242

Funding

National Research Centre(12010122)

National Research Centre Egypt